Will India’s Sun Rise On Stada? Bankers, Analysts Divided On Risks, Benefits
This article was originally published in PharmAsia News
Stada’s financial woes may not be primary factors for Sun to bid but analysts reason there may be value accretive points.
You may also be interested in...
Sun Finally Gains Control Of Taro As Founders Relent; Charts Out Aggressive Investment And Growth Plans
A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.